322 related articles for article (PubMed ID: 27097116)
1. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
Tao J; Xu E; Zhao Y; Singh S; Li X; Couchy G; Chen X; Zucman-Rossi J; Chikina M; Monga SP
Hepatology; 2016 Nov; 64(5):1587-1605. PubMed ID: 27097116
[TBL] [Abstract][Full Text] [Related]
2. Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice.
Tao J; Zhang R; Singh S; Poddar M; Xu E; Oertel M; Chen X; Ganesh S; Abrams M; Monga SP
Hepatology; 2017 May; 65(5):1581-1599. PubMed ID: 27981621
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
4. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.
Liang Y; Feng Y; Zong M; Wei XF; Lee J; Feng Y; Li H; Yang GS; Wu ZJ; Fu XD; Feng GS
Hepatology; 2018 May; 67(5):1807-1822. PubMed ID: 29152756
[TBL] [Abstract][Full Text] [Related]
5. Thyroid Hormone Receptor-β Agonist GC-1 Inhibits Met-β-Catenin-Driven Hepatocellular Cancer.
Puliga E; Min Q; Tao J; Zhang R; Pradhan-Sundd T; Poddar M; Singh S; Columbano A; Yu J; Monga SP
Am J Pathol; 2017 Nov; 187(11):2473-2485. PubMed ID: 28807594
[TBL] [Abstract][Full Text] [Related]
6. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
[TBL] [Abstract][Full Text] [Related]
7. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model.
Zhan N; Michael AA; Wu K; Zeng G; Bell A; Tao J; Monga SP
Gene Expr; 2018 May; 18(2):135-147. PubMed ID: 29409568
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice.
Qiao Y; Xu M; Tao J; Che L; Cigliano A; Monga SP; Calvisi DF; Chen X
BMC Cancer; 2018 Nov; 18(1):1093. PubMed ID: 30419856
[TBL] [Abstract][Full Text] [Related]
10. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model.
Delgado E; Okabe H; Preziosi M; Russell JO; Alvarado TF; Oertel M; Nejak-Bowen KN; Zhang Y; Monga SP
J Hepatol; 2015 Feb; 62(2):380-7. PubMed ID: 25457204
[TBL] [Abstract][Full Text] [Related]
11. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.
Charawi S; Just PA; Savall M; Abitbol S; Traore M; Metzger N; Ravinger R; Cavard C; Terris B; Perret C
J Pathol; 2019 Apr; 247(4):435-443. PubMed ID: 30566242
[TBL] [Abstract][Full Text] [Related]
12. Diverse Basis of β-Catenin Activation in Human Hepatocellular Carcinoma: Implications in Biology and Prognosis.
Okabe H; Kinoshita H; Imai K; Nakagawa S; Higashi T; Arima K; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Ishiko T; Yoshizumi T; Beppu T; Monga SP; Baba H; Maehara Y
PLoS One; 2016; 11(4):e0152695. PubMed ID: 27100093
[TBL] [Abstract][Full Text] [Related]
13. Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression.
Rebouissou S; Franconi A; Calderaro J; Letouzé E; Imbeaud S; Pilati C; Nault JC; Couchy G; Laurent A; Balabaud C; Bioulac-Sage P; Zucman-Rossi J
Hepatology; 2016 Dec; 64(6):2047-2061. PubMed ID: 27177928
[TBL] [Abstract][Full Text] [Related]
14. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.
Cieply B; Zeng G; Proverbs-Singh T; Geller DA; Monga SP
Hepatology; 2009 Mar; 49(3):821-31. PubMed ID: 19101982
[TBL] [Abstract][Full Text] [Related]
15. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
16. β-Catenin and Yes-Associated Protein 1 Cooperate in Hepatoblastoma Pathogenesis.
Min Q; Molina L; Li J; Adebayo Michael AO; Russell JO; Preziosi ME; Singh S; Poddar M; Matz-Soja M; Ranganathan S; Bell AW; Gebhardt R; Gaunitz F; Yu J; Tao J; Monga SP
Am J Pathol; 2019 May; 189(5):1091-1104. PubMed ID: 30794807
[TBL] [Abstract][Full Text] [Related]
17. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
19. Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice.
Qiao Y; Wang J; Karagoz E; Liang B; Song X; Shang R; Evert K; Xu M; Che L; Evert M; Calvisi DF; Tao J; Wang B; Monga SP; Chen X
Hepatology; 2019 Dec; 70(6):2003-2017. PubMed ID: 30737831
[TBL] [Abstract][Full Text] [Related]
20. Distinct pathways of genomic progression to benign and malignant tumors of the liver.
Tward AD; Jones KD; Yant S; Cheung ST; Fan ST; Chen X; Kay MA; Wang R; Bishop JM
Proc Natl Acad Sci U S A; 2007 Sep; 104(37):14771-6. PubMed ID: 17785413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
